A study to assess efficacy and safety of immune checkpoint inhibitors for metastatic renal cell carcinoma trial-ineligible patients as First-Line Therapy
Latest Information Update: 13 Jul 2022
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 13 Jul 2022 New trial record
- 05 Jul 2022 Results published in the Targeted Oncology